Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3–11 Years with Hepatitis C Genotype 1a

Introduction To assess the safety, efficacy, and pharmacokinetics of mini-tablet formulations of ombitasvir (OBV), paritaprevir (PTV), ritonavir, and dasabuvir (DSV) with or without ribavirin for 12 weeks in children infected with chronic hepatitis C virus (HCV) genotype (GT) 1. Methods This is an o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2020-07, Vol.37 (7), p.3299-3310
Hauptverfasser:	Rosenthal, Philip, Narkewicz, Michael R., Yao, Betty B., Jolley, Christopher D., Lobritto, Steven J., Wen, Jessica, Molleston, Jean P., Hsu, Evelyn K., Jonas, Maureen M., Zha, Jiuhong, Liu, Li, Leung, Daniel H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anilides - therapeutic use Antiviral Agents - therapeutic use Carbamates - therapeutic use Cardiology Child Child, Preschool Cyclopropanes - therapeutic use Cytochrome P-450 CYP3A Inhibitors - therapeutic use Drug Therapy, Combination Endocrinology Female Genotype Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C, Chronic - drug therapy Humans Internal Medicine Lactams, Macrocyclic - therapeutic use Life Sciences & Biomedicine Male Medicine Medicine & Public Health Medicine, Research & Experimental Oncology Original Research Pharmacology & Pharmacy Pharmacology/Toxicology Proline - analogs & derivatives Proline - therapeutic use Research & Experimental Medicine Rheumatology Ribavirin - therapeutic use Ritonavir - therapeutic use Science & Technology Sulfonamides - therapeutic use Tablets Uracil - analogs & derivatives Uracil - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!